Keywords : BPH

Effectiveness of Non Steroidal Anti Inflamatery Drug "Diclofenac Sodium" in Treatment of Nocturia in Benign Prostatic Hyperplasia Patien

Ayad Ali Al-Beer; Abdull-Sattar Jubaiir Allii; Ehab jasiim Muhammad

Iraqi Postgraduate Medical Journal, 2011, Volume 10, Issue 3, Pages 311-316

We explored the effectiveness of enteric coated diclofenac sodiumfor patients with benign prostatic hyperplasia (BPH) complaining of nocturia. A total of 30 BPH patients aged 50-75 years were enrolled in the study. They each took a single 50-mg tablet of diclofenac sodium prior to sleeping at night for 14 days in addition to their BPH treatments In the questionnaire ,21 of 30 patients (70%) felt more satisfaction than previous treatments.
In this study, we attempted to investigate the role of enteric coated diclofenac sodium (voltaren) in the therapeutic management of BPH patients with nocturia.
Thirty patient with BPH ( 63.6± 6.56 years old) more than two episodes of nocturia per night were involved. These patients had received standard drug therapy. Although these patients had received standard drug therapy for more than half a year, they had still three or more episodes of nocturia. The patients took a single dose of 50 mg of diclofenac sodium enteric coated at night prior to sleep. Before and 2 week after the initiation of this therapy, the effects of this treatment were assessed by frequency volume chart and a questionnaire.
In the questionnaire ,21 of 30 patients (70%) felt more satisfaction than previous treatments. Patients were grouped into a diclofenac sodium-effective (n = 23) and ineffective groups (n = 7) based on the results of the frequency-volume chart. In the effective group, interestingly, night-time urine volume showed significant reduction (P < 0.001). On the other hand, the average single voided volume at night showed no significant change. There was a statistically significant difference in the night-time urine volume after treatment between groups (P < 0.05). In frequency volume chart, total void per day, total void per night, total urine volume per day, total night urine volume per day and single voided volume in the night before and after this treatment were 9.9±0.56and 10.1±0.69per day, 3.9±0.87 and 2.3±1.1 per night, 1500.2±106.9 and1508.7±107.3 mL per day, 580.2±136.9 and 350.4±169.3 mL per night, and 150±7.2 and 150.4±7.05mL, respectively, in a diclofenac sodium-effective group.
Diclofenac sodium can be effective and useful for BPH patients with nocturia

Role of Anticholinergic Drugs in Patients with Benign Prostatic Hyperplasia Symptoms

Nassrat Abdul Mohsen. Nassir; Wisam Ali Kareem; Usama Sulaiman Al-Nasiri

Iraqi Postgraduate Medical Journal, 2010, Volume 9, Issue 1, Pages 41-47

We determined the efficacy and safety of combination therapy of α-blockers and anticholenergic drugs in patients with benign prostatic hyperplasia complain mainly of storage symptoms.
Study has been design to assess the efficacy and safety of combined treatment with oxybutynin plus tamsulosin in patients with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).
Prospective randomized controlled study of patients with moderate to severe lower urinary tract symptoms. Eligible patients were men 40 years and older with a total IPSS of 12 or higher; An IPSS quality-of-life (QOL) item score of 3 or higher. Additional inclusion criteria were micturition frequency (≥8 micturitions per 24 hours) and urgency (micturitions with urgency rating>3 per 24 hours) for 3 or more months. Men with clinically significant bladder outlet obstruction, or serum prostate-specific antigen of more than 4 ng/mL with risk of prostate cancer were excluded.
A total of 24(80%) patients receiving oxybutynin plus tamsulosin (Group3) reported treatment benefit by week 12 compared with 13(46.4%) patients receiving placebo (Group1) (P=0.02), 16 (53.4%) patients receiving tamsulosin(Group2) (P=0.45 vs. placebo), there is statistically significant difference between group 3 and group 2 with the p value 0.04. Patients receiving oxybutynin plus tamsulosin compared with placebo experienced significant reductions in urgency urinary incontinence, Urgency episodes, micturitions per 24 hours, and micturitions per night. Group3 Patients demonstrated significant improvements on the total International Prostate Symptom Score (−7.22 vs. −3.46 in G1, P=.003) and QOL item (−2.21 vs −1.17, In G1 P=.003). The incidence of acute urinary retention requiring catheterization was low in group3, the incidence was only 1 patient 3.3%; 3 patients(10.3%) in group1, while in tamsulosin group there was no patient complain of acute urinary retention 0% .
These results suggest that treatment with oxybutynin plus tamsulosin provides benefit for men with moderate to severe LUTS and BPH.